Cart 0

MarketsandMarkets

Humanized Mouse Model Market - Global Forecast to 2021

$5,650.00

Report Published By: MarketsandMarkets
Publication Date : Jan-17
No. Of Pages: 185

The humanized mouse model market is projected to reach USD 116.0 million by 2021 from USD 73.3 million in 2016, growing at a CAGR of 9.6% in the next five years (2016 to 2021).


Growing adoption of personalized medicine to fuel the demand for personalized mice models, continuous support in the form of investments and grants from the government and private sectors, and increase in R&D activities carried out by pharmaceutical and biotechnology companies are the key factors driving the growth of the market. However, regulations & laws formulated for ethical use of animals and increased use of rat models are restraining the growth of the market to a certain extent.

The global humanized mouse model market is segmented on the basis of type, application, end user, and region. In 2016, North America is expected to account for the largest share of the global humanized mouse model market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Asia-Pacific is projected to have the highest growth rate in the forecast period. The high growth rate of this segment can be attributed to factors such as increasing investments from the government and private sector in China, growing biomedical and medical research industry in Japan, growing presence of global players in India, and increasing pharmaceutical and biotech R&D activities in Korea.

The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (product launches, collaborations, agreements, partnerships, alliances, grants, licensing, contracts, acquisitions, and expansions) to increase their market shares and establish a strong foothold in the global market.

In-depth interviews were conducted with CEOs, Sales and Marketing Directors, other innovation and technology directors, and executives from various key organizations operating in the humanized mouse model market place.
? By Company Type: Tier 1: 50%, Tier 2: 42%, Tier 3: 8%
? By Designation: Director Level: 58%, C-level: 25%, Others: 17%
? By Region: North America: 46%, Europe: 31%, APAC: 15%, RoW: 8%
Key players in the global humanized mouse model market include The Jackson Laboratory (U.S.), Taconic Biosciences, Inc. (U.S.), Harbour Antibodies BV (China), HuMurine Technologies, Inc. (U.S.), Vitalstar Biotechnology Co. Ltd. (China), Crown Bioscience, Inc. (U.S.), ingenious targeting laboratory (U.S.), Axenis S.A.S (France), TRANS GENIC, Inc. (Japan), genOway S.A. (France), and Horizon Discovery Group plc (U.K.).

Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the products and services offered by top players in the humanized mouse model market. The report analyzes the humanized mouse market by type, application, and end user.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the humanized mouse model market
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for humanized mouse model across regions
• Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the humanized mouse model market
• Competitive Assessment: In-depth assessment of market shares, strategies, products, and distribution networks of the leading players in the humanized mouse model market

TABLE OF CONTENTS

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 17
1.3.1 MARKETS COVERED 17
1.3.2 YEARS CONSIDERED FOR THE STUDY 18
1.4 CURRENCY 18
1.5 LIMITATIONS 18
1.6 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 RESEARCH METHODOLOGY 20
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 21
2.2.1 SECONDARY RESEARCH 21
2.2.1.1 Key data from secondary sources 21
2.2.2 PRIMARY RESEARCH 23
2.2.2.1 Key data from primary sources 24
2.2.2.2 Key insights from primary sources 24
2.2.2.3 Key industry insights 25
2.3 MARKET SIZE ESTIMATION METHODOLOGY 26
2.4 MARKET FORECAST METHODOLOGY 28
2.5 MARKET DATA VALIDATION AND TRIANGULATION 29
2.6 ASSUMPTIONS FOR THE STUDY 29
3 EXECUTIVE SUMMARY 30
3.1 INTRODUCTION 30
3.2 CONCLUSION 35
4 PREMIUM INSIGHTS 36
4.1 HUMANIZED MOUSE MODEL: MARKET OVERVIEW 36
4.2 REGIONAL ANALYSIS: GLOBAL HUMANIZED MOUSE MODEL MARKET, BY END USER 37
4.3 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY APPLICATION, 2016 VS. 2021 38
4.4 REGIONAL SNAPSHOT: GLOBAL HUMANIZED MOUSE MODEL MARKET 38
?
5 MARKET OVERVIEW 39
5.1 INTRODUCTION 40
5.2 MARKET DYNAMICS 40
5.2.1 DRIVERS 41
5.2.1.1 Surge in the number of research activities involving humanized mouse models 41
5.2.1.1.1 Mice models for immunodeficiency disorders 41
5.2.1.1.2 Mice models for cancer 41
5.2.1.1.3 Mice models for rare diseases 42
5.2.1.2 Growing adoption of personalized medicine to fuel the demand for personalized mice models 42
5.2.1.3 Continuous support in the form of investments and grants from the government and private sectors 43
5.2.1.3.1 Funding/grants by the National Institutes of Health (NIH) 43
5.2.1.3.2 Funding/grants received from other government bodies 43
5.2.1.4 Increase in R&D activities carried out by pharmaceutical and biotechnology companies 44
5.2.2 RESTRAINTS 45
5.2.2.1 Regulations & laws formulated for ethical use of animals 45
5.2.2.1.1 The Animal Welfare Act (AWA) 45
5.2.2.1.2 Public Health Service (PHS) policy on humane care and use of laboratory animals 45
5.2.2.2 Increased use of rat models 45
5.2.3 OPPORTUNITIES 46
5.2.3.1 Increased production of monoclonal antibodies 46
5.2.4 CHALLENGES 47
5.2.4.1 Advances in zebrafish model development 47
5.2.4.2 Alternative methods of animal testing 47
5.2.4.3 Limitations of humanized mouse models 48
6 CLINICAL TRIALS & RESEARCH STUDIES ASSESSMENT 49
6.1 INTRODUCTION 50
6.2 CLINICAL TRIALS 50
6.3 RESEARCH STUDIES 54
7 HUMANIZED MOUSE MODEL MARKET, BY TYPE 56
7.1 INTRODUCTION 57
7.2 GENETIC HUMANIZED MOUSE MODEL 58
7.3 CELL-BASED HUMANIZED MOUSE MODEL 59
7.3.1 CD34 HUMANIZED MOUSE MODEL (HU-CD34) 61
7.3.2 PBMC HUMANIZED MOUSE MODEL 62
7.3.3 BLT HUMANIZED MOUSE MODEL 64
?
8 HUMANIZED MOUSE MODEL MARKET, BY APPLICATION 66
8.1 INTRODUCTION 67
8.2 ONCOLOGY 68
8.2.1 AGREEMENTS/COLLABORATIONS TO STRENGTHEN CANCER RESEARCH 69
8.2.2 CONTINUOUS GRANTS/FUNDS TO SUPPORT CANCER RESEARCH STUDIES 69
8.3 IMMUNOLOGY AND INFECTIOUS DISEASES 70
8.4 NEUROSCIENCES 71
8.4.1 GRANTS/FUNDS FOR NEUROLOGICAL RESEARCH 72
8.5 TOXICOLOGY 73
8.6 HEMATOPOIESIS 74
8.7 OTHER APPLICATIONS 76
8.7.1 INCREASING FUNDING FOR RARE DISEASE RESEARCH 76
9 HUMANIZED MOUSE MODEL MARKET, BY END USER 78
9.1 INTRODUCTION 79
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 80
9.3 CONTRACT RESEARCH ORGANIZATIONS 82
9.4 ACADEMIC & RESEARCH INSTITUTIONS 83
10 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY REGION 85
10.1 INTRODUCTION 86
10.2 NORTH AMERICA 88
10.2.1 U.S. 91
10.2.1.1 Availability of support for research in the U.S. 91
10.2.1.2 Preclinical activities by cros and pharmaceutical R&D 92
10.2.1.3 Conferences and other events contributing to the spread of innovation and awareness 92
10.2.1.4 Growing monoclonal antibody production 93
10.2.1.5 Development of biosimilars boosting the demand for preclinical services 94
10.2.2 CANADA 96
10.2.2.1 Growing stem cell research in Canada 96
10.2.2.2 Government support for development of protein drugs 97
10.3 EUROPE 99
10.3.1 LAUNCH OF PRO-TEST DEUTSCHLAND IN GERMANY 100
10.3.2 FLOURISHING BIOTECHNOLOGY INDUSTRY IN GERMANY 100
10.3.3 EMPHASIS ON QUALITY RESEARCH RESULTS IN THE U.K. 101
10.3.4 INCREASE IN CELL THERAPY PRECLINICAL RESEARCH IN THE U.K. 101
10.3.5 FUNDING FOR RARE DISEASE PROJECTS IN FRANCE 102
10.3.6 GROWTH IN BIOTECH AND PHARMA SECTOR OF ITALY 102
10.3.7 GROWING INVESTMENTS IN RESEARCH BY SWEDEN & DENMARK 103
?
10.4 ASIA-PACIFIC 105
10.4.1 CHINA: STRONG RESEARCH EXPENDITURE, WELL-STRUCTURED CRO INDUSTRY 106
10.4.2 MANDATORY ANIMAL TESTING FOR ALL PHARMACEUTICAL DRUGS AND COSMETICS IN CHINA 106
10.4.3 RISING FOCUS ON PERSONALIZED MEDICINE IN CHINA 106
10.4.4 INCREASING INVESTMENTS FROM GOVERNMENT AND PRIVATE SECTORS IN CHINA’S LIFE SCIENCES SECTOR 107
10.4.5 JAPAN: GOVERNMENT SUPPORT FOR RESEARCH, GROWTH IN BIOMEDICAL AND MEDICAL RESEARCH 108
10.4.6 RESEARCH IN REGENERATIVE MEDICINE IN JAPAN 108
10.4.7 GROWTH OF THE PHARMACEUTICAL INDUSTRY IN INDIA 109
10.4.8 DEVELOPMENT OF BIO-CLUSTERS TO BOOST INDIA’S BIOTECHNOLOGY SECTOR 109
10.4.9 INFRASTRUCTURAL LIMITATIONS IN INDIA: A KEY HINDRANCE FOR MARKET GROWTH 110
10.4.10 ONGOING BIOMEDICAL RESEARCH ACTIVITIES IN AUSTRALIA 110
10.4.11 GROWTH IN TRANSLATIONAL AND BIOMEDICAL RESEARCH IN SINGAPORE 111
10.4.12 INCREASE IN ANIMAL RESEARCH IN MALAYSIA 112
10.4.13 RISING PHARMACEUTICAL AND BIOTECHNOLOGY R&D ACTIVITIES IN KOREA 112
10.5 REST OF THE WORLD 115
10.5.1 BRAZIL: GROWTH IN THE PHARMACEUTICAL, BIOTECHNOLOGY, AND RESEARCH INDUSTRIES 116
10.5.2 FAVORABLE BUSINESS ENVIRONMENT FOR PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES IN SAUDI ARABIA AND THE UAE 116
10.5.3 INCREASING INVESTMENTS IN MEXICO 117
11 COMPETITIVE LANDSCAPE 119
11.1 OVERVIEW 119
11.2 MARKET SHARE ANALYSIS 120
11.2.1 INTRODUCTION 120
11.2.2 CELL-BASED HUMANIZED MOUSE MODEL MARKET 120
11.2.2.1 The jackson laboratory (U.S.) 121
11.2.2.2 Taconic biosciences, inc. (U.S.) 121
11.2.3 GENETIC HUMANIZED MOUSE MODEL MARKET 122
11.2.3.1 Horizon discovery group plc (U.K.) 122
11.2.3.2 Taconic biosciences, inc. (U.S.) 123
11.3 COMPETITIVE SITUATION AND TRENDS 123
11.4 AGREEMENTS, COLLABORATIONS, CONTRACTS, ALLIANCES, AND PARTNERSHIPS 124
11.5 GRANT/FUND 126
11.6 PRODUCT LAUNCHES 127
11.7 EXPANSIONS 128
11.8 ACQUISITIONS 129
11.9 OTHER STRATEGIES 130
12 COMPANY PROFILES 132
(Overview, Products and Services, Financials, Strategy & Development)*
12.1 INTRODUCTION 132
12.2 THE JACKSON LABORATORY 133
12.3 TACONIC BIOSCIENCES, INC. 138
12.4 HORIZON DISCOVERY GROUP PLC 141
12.5 GENOWAY S.A. 145
12.6 HARBOUR ANTIBODIES BV (A SUBSIDIARY OF HARBOUR BIOMED) 148
12.7 HUMURINE TECHNOLOGIES 149
12.8 VITALSTAR BIOTECHNOLOGY CO., LTD. 150
12.9 INGENIOUS TARGETING LABORATORY 151
12.10 AXENIS S.A.S 152
12.11 TRANS GENIC, INC. 153
12.12 CHAMPIONS ONCOLOGY, INC. 156
12.13 CROWN BIOSCIENCE, INC. 159
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
13 APPENDIX 162
13.1 DISCUSSION GUIDE 162
13.2 OTHER DEVELOPMENTS (2013–2016) 166
13.2.1 THE JACKSON LABORATORY 166
13.2.2 TACONIC BIOSCIENCES, INC. 169
13.2.3 HORIZON DISCOVERY GROUP PLC 170
13.2.4 GENOWAY S.A. 171
13.2.5 INGENIOUS TARGETING LABORATORY 172
13.2.6 TRANS GENIC, INC. 172
13.2.7 CHAMPIONS ONCOLOGY, INC. 173
13.2.8 CROWN BIOSCIENCE, INC. 174
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 177
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 179
13.5 AVAILABLE CUSTOMIZATIONS 180
13.6 RELATED REPORTS 181
13.7 AUTHOR DETAILS 182

* indicates required information

* indicates required information


Share this Product


More from this collection